Cited by 400Liver Disease Diagnosis and TreatmentLiver Disease and TransplantationLiver Diseases and Immunity

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

Boursier, Jérôme, Vergniol, Julien, Guillet, Anne, Hiriart, Jean-Baptiste, Lannes, Adrien, Le Bail, Brigitte, Michalak, Sophie, Chermak, Faiza, Bertrais, Sandrine, Foucher, Juliette, Oberti, Frédéric, Charbonnier, Maude, Fouchard-Hubert, Isabelle, Rousselet, Marie-Christine, Calès, Paul, de Lédinghen, Victor·2016·Journal of Hepatology

DOI 10.1016/j.jhep.2016.04.023

Open this paper in CoChat — free account

Abstract

Background & aims NAFLD is highly prevalent but only a small subset of patients develop advanced liver fibrosis with impaired liver-related prognosis. We aimed to compare blood fibrosis tests and liver stiffness measurement (LSM) by FibroScan for the diagnosis of liver fibrosis and the evaluation of prognosis in NAFLD.Methods Diagnostic accuracy was evaluated in a cross-sectional study including 452 NAFLD patients with liver biopsy (NASH-CRN fibrosis stage), LSM, and eight blood fibrosis tests (BARD, NAFLD fibrosis score, FibroMeter(NAFLD), aspartate aminotransferase to platelet ratio index (APRI), FIB4, FibroTest, Hepascore, FibroMeter(V2G)). Prognostic accuracy was evaluated in a longitudinal study including 360 NAFLD patients.Results LSM and FibroMeter(V2G) were the two best-performing tests in the cross-sectional study: AUROCs for advanced fibrosis (F3/4) were, respectively, 0.831±0.019 and 0.817±0.020 (p⩽0.041 vs. other tests); rates of patients with ⩾90% negative/positive predictive values for F3/4 were 56.4% and 46.7% (p<0.001 vs. other tests); Obuchowski indexes were 0.834±0.014 and 0.798±0.016 (p⩽0.036 vs. other tests). Two fibrosis classifications were developed to precisely estimate the histological fibrosis stage from LSM or FibroMeter(V2G) results without liver biopsy (diagnostic accuracy, respectively: 80.8% vs. 77.4%, p=0.190). Kaplan-Meier curves in the longitudinal study showed that both classifications categorised NAFLD patients into subgroups with significantly different prognoses (p<0.001): the higher was the class of the fibrosis classification, the worse was the prognosis.Conclusions LSM and FibroMeter(V2G) were the most accurate of nine evaluated tests for the non-invasive diagnosis of liver fibrosis in NAFLD. LSM and FibroMeter(V2G) fibrosis classifications help physicians estimate both fibrosis stage and patient prognosis in clinical practice.Lay summary The amount of liver fibrosis is the main determinant of the liver-related prognosis in patients with non-alcoholic fatty liver disease (NAFLD). We evaluated eight blood tests and FibroScan in a cross-sectional diagnostic study and found that FibroScan and the blood test FibroMeter(V2G) were the two most accurate tests for the non-invasive evaluation of liver fibrosis in NAFLD. A longitudinal prognostic study showed these two tests initially developed for the diagnosis are also prognostic markers as they allow for the stratification of NAFLD patients in several subgroups with significantly different prognosis.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2016.04.023

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 10×
“Eight blood fibrosis tests were calculated according to published or patented formulas: NFS (12), BARD (20), FibroMeter NAFLD (21), APRI (22), FIB4 (23), Fibrotest (24), Hepascore (25), and FibroMeter V2G (26).”
MethodInfluential
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
The NAFLD fibrosis score
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,244
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Liver Biopsy
Bravo, A. A., Sheth, S. G., & Chopra, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440706 · Cited by 2,047
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,805
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748

Flagged first, then by citations

Show all 45 references

Sorted by citations

Items 101–200 of 398

The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Gunn, N., & Shiffman, M. L. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.006 · Cited by 56
Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non‐alcoholic fatty liver disease from tertiary care centres
Guillaume, M., Moal, V., Delabaudière, C., Zuberbuhler, F., Robic, M., Lannes, A., Métivier, S., Oberti, F., Gourdy, P., Fouchard‐Hubert, I., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15529 · Cited by 55
Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: a randomized trial
Marin‐Alejandre, B. A., Cantero, I., Perez‐Diaz‐del‐Campo, N., Monreal, J. I., Elorz, M., Herrero, J. I., Benito‐Boillos, A., Quiroga, J., Martinez‐Echeverria, A., Uriz‐Otano, J. I., et al. (2021) · Liver International · doi:10.1111/liv.14818 · Cited by 54
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Patel, K., Asrani, S. K., Fiel, M. I., Levine, D., Leung, D. H., Duarte‐Rojo, A., Dranoff, J. A., Nayfeh, T., Hasan, B., Taddei, T. H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000842 · Cited by 60
Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?
Lai, J. C., Liang, L. Y., & Wong, G. L. (2023) · Gastroenterology report · doi:10.1093/gastro/goae024 · Cited by 50
Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance
Aubé, C., Bazeries, P., Lebigot, J., Cartier, V., & Boursier, J. (2017) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2017.03.003 · Cited by 48
Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities
Trzépizur, W., Boursier, J., Vaillant, M. L., Ducluzeau, P., Dubois, S. G., Henni, S., Abraham, P., Aubé, C., Calès, P., & Gagnadoux, F. (2018) · European Respiratory Journal · doi:10.1183/13993003.00601-2018 · Cited by 48
MACK‐3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non‐alcoholic steatohepatitis
Chuah, K. H., Yusoff, W. N. I. W., Sthaneshwar, P., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2019) · Liver International · doi:10.1111/liv.14084 · Cited by 48
Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness
Chow, J. C., Wong, G. L., Chan, A. W., Shu, S. S., Chan, C. K., Leung, J. K., Choi, P. C., Chim, A. M., Chan, H. L., & Wong, V. W. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14311 · Cited by 46
The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Fouad, Y. M., Esmat, G., Elwakil, R., Zakaria, S., Yosry, A., Waked, I. A., El-Razky, M., Doss, W. H., El‐Serafy, M., Mostafa, E., et al. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_357_21 · Cited by 49
Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease
Altamirano, J., Qi, Q., Choudhry, S., Abdallah, M., Singal, A. K., Humar, A., Bataller, R. A., Borhani, A. A., & Duarte‐Rojo, A. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.11.14 · Cited by 45
Recent advances in understanding and managing non-alcoholic fatty liver disease
Albhaisi, S. A. M., & Sanyal, A. J. (2018) · F1000Research · doi:10.12688/f1000research.14421.1 · Cited by 44
Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease.
Miele, L., Zocco, M., Pizzolante, F., Matthaeis, N. D., Ainora, M., Liguori, A., Gasbarrini, A., Grieco, A., & Rapaccini, G. (2020) · Metabolism: Clinical and Experimental · doi:10.1016/j.metabol.2020.154355 · Cited by 42
Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease
van Dijk, A., Vali, Y., Mak, A. L., Lee, J., Tushuizen, M. E., Zafarmand, M. H., Anstee, Q. M., Brosnan, M. J., Nieuwdorp, M., Bossuyt, P. M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132910 · Cited by 46
CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population
Gómez, E. V., Vuppalanchi, R., Gawrieh, S., Samala, N. R., & Chalasani, N. (2023) · Hepatology · doi:10.1097/hep.0000000000000023 · Cited by 44
Changing clinical management of NAFLD in Asia
Nakatsuka, T., Tateishi, R., & Koike, K. (2021) · Liver International · doi:10.1111/liv.15046 · Cited by 44
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
Munteanu, M., Pais, R., Peta, V., Deckmyn, O., Moussalli, J., Ngo, Y., Rudler, M., Lebray, P., Charlotte, F., Thibault, V., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14990 · Cited by 42
Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis
Pennisi, G., Enea, M., Romero‐Gomez, M., Viganò, M., Bugianesi, E., Wong, V. W. ‐., Fracanzani, A. L., Sebastiani, G., Boursier, J., Berzigotti, A., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16763 · Cited by 43
Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non‐invasive score
Xin, Z., Zhu, Y., Wang, S., Liu, S., Xu, M., Wang, T., Lu, J., Chen, Y., Zhao, Z., Wang, W., et al. (2019) · Liver International · doi:10.1111/liv.14322 · Cited by 42
Screening for nonalcoholic fatty liver disease-when, who and how?
Dietrich, C. G., Rau, M., & Geier, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5803 · Cited by 44
The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018
Liu, J., Tan, L., Liu, Z., & Shi, R. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2110277 · Cited by 41
Local care and treatment of liver disease (LOCATE) – A cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care
El-Gohary, M., Moore, M. V., Roderick, P. J., Watkins, E., Dash, J., Reinson, T., Newell, C., Kim, M., Stuart, B. L., Becque, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208798 · Cited by 41
Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
Tovo, C. V., Villela‐Nogueira, C. A., Leite, N. C., Panke, C. L., Port, G. Z., Fernandes, S. A., Buss, C., Coral, G. P., Cardoso, A. C., Cravo, C. M., et al. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2018.09.003 · Cited by 40
Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment
Molina‐Molina, E., Krawczyk, M. J., Stachowska, E., Lammert, F., & Portincasa, P. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.04.005 · Cited by 40
High Meat Consumption Is Prospectively Associated with the Risk of Non-Alcoholic Fatty Liver Disease and Presumed Significant Fibrosis
Wajcman, D. I., Isakov, N. F., Grinshpan, L. S., Salomone, F., Lazarus, J. V., Webb, M., Shibolet, O., Kariv, R., & Zelber‐Sagi, S. (2022) · Nutrients · doi:10.3390/nu14173533 · Cited by 39
ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver‐Related Cirrhosis
Bertot, L. C., Vilar‐Gómez, E., Wong, V. W., Romero‐Gómez, M., la Fuente, R. A., Wong, G. L., Castellanos, M., Eslam, M., Desai, A. P., Jeffrey, G. P., et al. (2020) · Hepatology · doi:10.1002/hep.31576 · Cited by 39
Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort
Chang, M., Chang, D. Y., Kodali, S., Harrison, S. A., Ghobrial, R. M., Alkhouri, N., & Noureddin, M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.02.008 · Cited by 37
Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease
Kamarajah, S. K., Chan, W., Mustapha, N. R. N., & Mahadeva, S. (2018) · Hepatology International · doi:10.1007/s12072-018-9843-4 · Cited by 36
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 70
Nonalcoholic fatty liver disease, liver fibrosis, and structural brain imaging: The Cross‐Cohort Collaboration
Weinstein, G., O’Donnell, A., Frenzel, S., Xiao, T., Yaqub, A., Yilmaz, P., de Knegt, R. J., Maestre, G. E., van Lent, D. M., Long, M. T., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.16048 · Cited by 36
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Chon, Y. E., Jin, Y., An, J., Kim, H. Y., Choi, M., Jun, D. W., Kim, M. N., Han, J. W., Lee, H. A., Yu, J. H., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0392 · Cited by 36
Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis
Țâru, M.-G., Leucuta, D.-C., Lupșor‐Platon, M., Turco, L., Ferri, S., Hashim, A., Orasan, O. H., Procopeț, B., Ştefănescu, H., Morelli, M. C., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001190 · Cited by 43
Systematic review and meta‐analysis: non‐invasive detection of non‐alcoholic fatty liver disease related fibrosis in the obese
Ooi, G., Mgaieth, S., Eslick, G. D., Burton, P. R., Kemp, W. W., Roberts, S. K., & Brown, W. A. (2017) · Obesity Reviews · doi:10.1111/obr.12628 · Cited by 35
Plasma proteomic signature of fatty liver disease: The Rotterdam Study
Abozaid, Y. J., Ayada, I., van Kleef, L. A., Vallerga, C. L., Pan, Q., Brouwer, W. P., Ikram, M. A., van Meurs, J. B. J., de Knegt, R. J., & Ghanbari, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000300 · Cited by 34
Liver stiffness progression in biopsy-proven metabolic dysfunction–associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study
Huang, D. Q., Wilson, L., Behling, C. A., Amangurbanova, M., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001015 · Cited by 39
Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?
Canivet, C. M., & Boursier, J. (2022) · Diagnostics · doi:10.3390/diagnostics13010091 · Cited by 35
Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD ‐related liver fibrosis
Fan, R., Yu, N., Li, G., Arshad, T., Liu, W., Wong, G. L., Liang, X., Chen, Y., Jin, X., Leung, H. H. W., et al. (2023) · Liver International · doi:10.1111/liv.15818 · Cited by 33
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 34
A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post–liver transplant patient
Winters, A. C., Mittal, R., & Schiano, T. D. (2019) · Clinical Transplantation · doi:10.1111/ctr.13700 · Cited by 33
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
Wang, Y., Song, S. J., Jiang, Y., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0246 · Cited by 32
Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity
Ooi, G., Earnest, A., Kemp, W. W., Burton, P. R., Laurie, C., Majeed, A., Johnson, N. A., McLean, C., Roberts, S. K., & Brown, W. A. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0007-3 · Cited by 32
Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) – an 11-Year Prospective Study
Lallukka, S., Sädevirta, S., Kallio, M. T., Luukkonen, P. K., Zhou, Y., Hakkarainen, A., Lundbom, N. M. I., Orho‐Melander, M., & Yki‐Järvinen, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-14706-0 · Cited by 31
Recomendaciones para la detección, diagnóstico y seguimiento de los pacientes con enfermedad por hígado graso no alcohólico en atención primaria y hospitalaria
Caballería, L., Augustín, S., Broquetas, T., Morillas, R. M., Vergara, M., Virolés, S., Hernández, M. R., Serra, I., Goday, A., Vila, L., et al. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2019.01.030 · Cited by 31
Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease
Lee, Y., Yoo, Y. J., Jung, Y. K., Kim, J. H., Seo, Y. S., Yim, H. J., Kim, I. H., Lee, S. Y., Kim, B., Kim, J. W., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000157 · Cited by 31
Use of Steatotic Grafts in Liver Transplantation: Current Status
Álvarez‐Mercado, A. I., Gulfo, J., Romero‐Gómez, M., Jiménez‐Castro, M. B., Gracia‐Sancho, J., & Peralta, C. (2019) · Liver Transplantation · doi:10.1002/lt.25430 · Cited by 31
Advancements of non‐invasive imaging technologies for the diagnosis and staging of liver fibrosis: Present and future
Huang, W., Peng, Y., & Kang, L. (2024) · Open Research (University of Surrey) · doi:10.1002/viw.20240010 · Cited by 32
Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
Braude, M. R., Roberts, S. K., Majeed, A., Lubel, J. S., Prompen, J., Dev, A. T., Sievert, W., Bloom, S., Gow, P. J., & Kemp, W. W. (2022) · Liver International · doi:10.1111/liv.15415 · Cited by 29
Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS)–April 2022–AWMF Registration No.: 021–025
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Advances in ultrasound elastography for nonalcoholic fatty liver disease
Yoneda, M., Honda, Y., Nogami, A., Imajo, K., & Nakajima, A. (2020) · Journal of Medical Ultrasonics · doi:10.1007/s10396-020-01040-8 · Cited by 29
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
Tovo, C. V., de Mattos, Â. Z., Coral, G. P., SARTORI, G. D. P., Nogueira, L. V., Both, G. T., Villela‐Nogueira, C. A., & de Mattos, Â. A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.343 · Cited by 35
The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers
Safari, Z., Bagherniya, M., Khoram, Z., Varzaneh, A. E., Heidari, Z., Sahebkar, A., & Askari, G. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1163950 · Cited by 30
Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection
Maurice, J. B., Goldin, R. D., Hall, A. R., Price, J. C., Sebastiani, G., Morse, C. G., Prat, L. I., Perazzo, H., Garvey, L. J., Ingiliz, P., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1302 · Cited by 27
Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers
Viganò, M., Pugliese, N., Cerini, F., Turati, F., Cimino, V., Ridolfo, S., Rocchetto, S., Foglio, F., Terrin, M., Vecchia, C. L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012489 · Cited by 27
A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases
Ducancelle, A., Leroy, V., Vergniol, J., Stürm, N., Bail, B. L., Zarski, J., Khac, E. N., Salmon, D., de Lédinghen, V., & Calès, P. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000788 · Cited by 27
Mechanical properties of human hepatic tissues to develop liver-mimicking phantoms for medical applications
Lemine, A. S., Ahmad, Z., Al-Thani, N. J., Hasan, A., & Bhadra, J. (2023) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-023-01785-4 · Cited by 28
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants
Torrez, S. L., Ayala, C. O., Ruggiro, P. B., Costa, C. A. D., Wagner, M. B., Padoin, A. V., & Mattiello, R. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1284509 · Cited by 25
Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
Chan, W., Petta, S., Noureddin, M., Goh, G. B., & Wong, V. W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17866 · Cited by 25
Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination?
Calès, P., Boursier, J., Lebigot, J., de Lédinghen, V., Aubé, C., Hubert, I., & Oberti, F. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13954 · Cited by 25
Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?
Ajmera, V. H., & Loomba, R. S. (2018) · Seminars in Liver Disease · doi:10.1055/s-0037-1618587 · Cited by 25
Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients
Zelber‐Sagi, S., Shoham, D., Zvibel, I., Abu‐Abeid, S., Shibolet, O., & Fishman, S. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i2.91 · Cited by 24
Fibrosis regression following hepatitis C antiviral therapy
Elsharkawy, A. M., Samir, R., & El‐Kassas, M. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i6.1120 · Cited by 24
FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases
Zachou, K., Lygoura, V., Arvaniti, P., Giannoulis, G., Gatselis, N., Koukoulis, G. Κ., & Dalekos, G. N. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.10.013 · Cited by 24
Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
Westfall, E. C., Jeske, R., & Bader, A. R. (2020) · PubMed · Cited by 24
Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes
Chun, H. S., Lee, J. S., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Lee, Y., Kim, Y. D., & Kim, S. U. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15387 · Cited by 23
Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
Huisman, T. M., Dieterich, D. T., & Friedman, S. L. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265286 · Cited by 22
Development of fully automated models for staging liver fibrosis using non-contrast MRI and artificial intelligence: a retrospective multicenter study
Li, C., Wang, Y., Bai, R., Zhao, Z., Li, W., Zhang, Q., Zhang, C., Yang, W. J., Liu, Q., Su, N., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102881 · Cited by 22
NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF NON-ALCOHOLIC FATTY LIVER DISEASE.
Boursier, J., Guillaume, M., Bouzbib, C., Lannes, A., Pais, R., Smatti, S., Cariou, B., Bureau, C., Ganne-Carrié, N., Bourlière, M., et al. (2021) · Clinics And Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101769 · Cited by 21
Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease
Wang, J., Qin, T., Sun, J.-Y., Li, S., Cao, L., & Lu, X. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1046497 · Cited by 22
Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms
Lykiardopoulos, B., Hagström, H., Fredrikson, M. G., Ignatova, S., Stal, P. I., Hultcrantz, R. W., Ekstedt, M., & Kechagias, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167776 · Cited by 22
Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future
Adams, L. A., & Chan, W. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1713006 · Cited by 22
Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Bertot, L. C., Jeffrey, G. P., de Boer, B., Wang, Z., Huang, Y., Garas, G., MacQuillan, G. C., Wallace, M., Smith, B. W., & Adams, L. A. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07896-3 · Cited by 21
Liver stiffness predicts progression to liver‐related events in patients with chronic liver disease – A cohort study of 14 414 patients
Hegmar, H., Wester, A., Aleman, S., Backman, J., Degerman, E., Ekvall, H., Lund, K., Lundgren, Å., Nasr, P., Shahnavaz, A., et al. (2024) · Liver International · doi:10.1111/liv.15919 · Cited by 21
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage
Lombardi, R., Petta, S., Pisano, G., Dongiovanni, P., Rinaldi, L., Adinolfi, L. E., Acierno, C., Valenti, L. V. C., Boemi, R., Spatola, F., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.011 · Cited by 21
Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease
Cho, Y., Choi, Y. I., Oh, S., Han, J., Joo, S. K., Lee, D. H., Jung, Y. J., Kim, B. G., Lee, K. L., & Kim, W. K. (2019) · Hepatology International · doi:10.1007/s12072-019-10009-w · Cited by 21
Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus non-invasive assessment scores in patients with non-alcoholic fatty liver disease
Mansour, A. M. F., Bayoumy, E., ElGhandour, A. M., El-Talkawy, M. D., Badr, S. M., & Ahmed, A. E. (2020) · Egyptian Liver Journal · doi:10.1186/s43066-020-00044-w · Cited by 21
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 23
Interplay between non‐alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population
Pennisi, G., Marco, V. D., Buscemi, C., Mazzola, G. C., Randazzo, C., Spatola, F., Craxı̀, A., Buscemi, S., & Petta, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15523 · Cited by 22
Non-alcoholic fatty liver disease is not independently associated with Helicobacter pylori in a central European screening cohort
Wernly, S., Wernly, B., Semmler, G., Völkerer, A., Rezar, R., Semmler, L., Stickel, F., Aigner, E. S., Niederseer, D., & Datz, C. (2022) · Minerva Medica · doi:10.23736/s0026-4806.22.07928-9 · Cited by 20
The mid-infrared spectroscopy: A novel non-invasive diagnostic tool for NASH diagnosis in severe obesity
Anty, R., Morvan, M., Corvec, M. L., Canivet, C. M., Patouraux, S., Gugenheim, J., Bonnafous, S., Bailly‐Maitre, B., Sire, O., Tariel, H., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.09.005 · Cited by 20
Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography
Lupșor‐Platon, M., Serban, T., Silion, A. I., Tirpe, A., & Florea, M. (2020) · Cancers · doi:10.3390/cancers12102778 · Cited by 20
Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results
Halfon, P., Ansaldi, C., Pénaranda, G., Chiche, L., Dukan, P., Stavris, C., Plauzolles, A., Rétornaz, F., & Bourlière, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254939 · Cited by 19
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
Sanyal, A. J., Muñoz, B., Cusi, K. J., Barritt, A. S., Muthiah, M. D., Mospan, A. R., Reddy, K. R., Firpi-Morell, R. J., Thuluvath, P. J., Bhamidimarri, K. R., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.024 · Cited by 19
Long‐term prognosis of patients with metabolic (dysfunction)‐associated fatty liver disease by non‐invasive methods
Decraecker, M., Dutartre, D., Hiriart, J., Irlès‐Depé, M., Chermak, F., Foucher, J., & de Lédinghen, V. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16760 · Cited by 19
Cross-Domain Missingness-Aware Time-Series Adaptation With Similarity Distillation in Medical Applications
Yang, B., Ye, M., Tan, Q., & Yuen, P. C. (2020) · IEEE Transactions on Cybernetics · doi:10.1109/tcyb.2020.3011934 · Cited by 19
Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography
Berzigotti, A. (2015) · Reviews on Recent Clinical Trials · doi:10.2174/1574887109666141216101630 · Cited by 18
Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?
García‐Compeán, D., Villarreal‐Pérez, J. Z., de la O-Cavazos, M. E., Lavalle-Gonzalez, F. J., Borjas-Almaguer, O. D., del Cueto-Aguilera, Á. N., González, J. A., Treviño‐Garza, C., Huerta-Pérez, L., & Maldonado-Garza, H. J. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.01.003 · Cited by 18
Accuracy of Controlled Attenuation Parameter and Liver Stiffness Measurement in Patients with Non-alcoholic Fatty Liver Disease
Mikolašević, I., Domislović, V., Klapan, M., Jurić, T., Lukic, A., Zrnić, I. K., Čupić, D. F., Štimac, D., Kanižaj, T. F., Krznarić, Ž., et al. (2021) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2020.11.015 · Cited by 18
Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Kogachi, S., & Noureddin, M. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.012 · Cited by 18
Liver disease with unknown etiology – have you ruled out alpha-1 antitrypsin deficiency?
Patel, D. R., & Teckman, J. H. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622321995684 · Cited by 18
Non-Alcoholic Fatty Liver Disease and Vascular Disease
Forlano, R., Mullish, B. H., Nathwani, R., Dhar, A., Thursz, M. R., & Manousou, P. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118666200318103001 · Cited by 18
Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome
Han, M. A. T. (2020) · Life · doi:10.3390/life10090198 · Cited by 17
Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease
Li, J., Delamarre, A., Wong, V. W., & de Lédinghen, V. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12491 · Cited by 15
Quantitative Imaging in Diffuse Liver Diseases
Garteiser, P., Leporq, B., Rautou, P., Valla, D. C., & BEERS, B. E. V. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1603651 · Cited by 16
End-points for drug treatment in NASH
Adams, L. A. (2019) · Hepatology International · doi:10.1007/s12072-019-09935-6 · Cited by 16
Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study
Bilgin, B. Ö., Sünbül, M., Kani, H. T., Demirtaş, C. Ö., Keklikkıran, Ç., & Yilmaz, Y. N. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001471 · Cited by 16
Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE Thresholds and Diagnostic Accuracies for Detecting Hepatic Fibrosis in Patients with MASLD: A Systematic Review and Meta-Analysis
Wilson, M. P., Singh, R., Mehta, S., Murad, M. H., Fung, C. I., & Low, G. (2025) · Diagnostics · doi:10.3390/diagnostics15131598 · Cited by 21
Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference
Arieira, C., Monteiro, S., Xavier, S. A., de Castro, F. D., Magalhães, J. T., Moreira, M. J., Marinho, C. M. M., & Cotter, J. B. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001319 · Cited by 15
Adiponectin involved in portal flow hepatic extraction of 13C-methacetin in obesity and non-alcoholic fatty liver
Ciaula, A. D., Carbone, F., Shanmugam, H., Molina‐Molina, E., Bonfrate, L., Ministrini, S., Montecucco, F., & Portincasa, P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.03.036 · Cited by 15
Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept “Compensated Advanced Chronic Liver Disease”
Fujita, K., & Masaki, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153340 · Cited by 15

Authors: Boursier, J., Vergniol, J., Guillet, A., Hiriart, J.-B., Lannes, A., Le Bail, B., Michalak, S., Chermak, F., Bertrais, S., Foucher, J., Oberti, F., Charbonnier, M., Fouchard-Hubert, I., Rousselet, M.-C., Calès, P., & de Lédinghen, V.
Affiliations: Centre Hospitalier Universitaire d'Angers (FR)
Centre Hospitalier Universitaire de Bordeaux (FR)
Université d'Angers (FR)
Université Nantes Angers Le Mans (FR)
Corresponding author: Boursier, Jérôme
ORCID: Boursier, Jérôme
Hiriart, Jean-Baptiste
Bertrais, Sandrine
Foucher, Juliette
Oberti, Frédéric
Rousselet, Marie-Christine
Calès, Paul
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2016-09
Volume: 65
Issue: 3
Pages: 570-578
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2016.04.023
OpenAlex: W2346887577
Cited by: 400
References: 45
Citations by year: 2026: 15 · 2025: 27 · 2024: 40 · 2023: 38 · 2022: 47 · 2021: 60 · 2020: 51 · 2019: 47 · 2018: 35 · 2017: 31 · 2016: 6
FWCI: 37.13
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: non-alcoholic fatty liver disease, liver fibrosis, liver stiffness measurement, FibroScan, noninvasive fibrosis assessment, prognostic accuracy, NAFLD fibrosis score, APRI, FIB-4, fibrosis staging, liver biopsy alternative, liver-related mortality
MeSH terms: Biopsy, Cross-Sectional Studies, Humans, Liver Cirrhosis, Longitudinal Studies, Prognosis, Biomarkers, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks